Patents by Inventor Jörn Görlach

Jörn Görlach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6858404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: February 22, 2005
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6800459
    Abstract: The present inventors have discovered that chorismate mutase and chorismate synthase are essential for plant growth. Specifically, the inhibition of chorismate mutase or chorismate synthase gene expression in plant seedlings results in severe chlorosis, reduced growth and developmental abnormalities. The inventors have proven that chorismate synthase and chorismate mutase can be used as targets for the identification of herbicides. Thus, the invention provides methods for the identification of chemicals that modulate chorismate synthase and chorismate mutase biochemical reactions. The methods of the invention are useful for the identification of herbicides and for the inhibition of plant growth and development.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: October 5, 2004
    Assignee: Paradigm Genetics, Inc.
    Inventors: Douglas C. Boyes, Keith R. Davis, Jeffrey P. Woessner, Jörn Görlach, Carol M. Hamilton, Neil E. Hoffman, Andreas S. Klöti, Adel Zayed, Robert A. Ascenzi
  • Patent number: 6582900
    Abstract: The present inventors have discovered that Mg-chelatase is essential for the growth of Arabidopsis. Specifically, the inhibition of Mg-chelatase CHL H gene expression in Arabidopsis seedlings results in varying levels of chlorosis (yellowing), significantly reduced growth and developmental abnormalities. Thus, Arabidopsis Mg-chelatase can be used as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of compounds that modulate Arabidopsis Mg-chelatase expression or activity, comprising: contacting a compound with a Arabidopsis Mg-chelatase, or a subunit thereof, and detecting the presence and/or absence of binding between said compound and said Mg-chelatase, or detecting a change in Mg-chelatase expression or activity. The methods of the invention are useful for the identification of herbicides and other compounds that can modulate plant growth and development.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: June 24, 2003
    Assignee: Paradigm Genetics, Inc.
    Inventors: Jeffrey P. Woessner, Adel Zayed, Jörn Görlach, Douglas C. Boyes, Keith R. Davis, Carol M. Hamilton, Neil E. Hoffman, Andreas S. Kloti, Robert A. Ascenzi
  • Patent number: 6465217
    Abstract: The present inventors have discovered that chorismate mutase and chorismate synthase are essential for plant growth. Specifically, the inhibition of chorismate mutase or chorismate synthase gene expression in plant seedlings results in severe chlorosis, reduced growth and developmental abnormalities. Thus, in one aspect the invention provides compositions for the modulation of plant growth or development comprising chorismate synthase and chorismate mutase antisense and sense polynucleotides, dsRNA and ribozymes, and related expression cassettes and vectors. The compositions of the invention are particularly useful for the modulation and inhibition of plant growth. The invention further provides plants, plant cells, and seeds containing the polynucleotides of the invention. The inventors have proven that chorismate synthase and chorismate mutase can be used as targets for the identification of herbicides.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: October 15, 2002
    Assignee: Paradigm Genetics, Inc.
    Inventors: Douglas C. Boyes, Keith R. Davis, Jeffrey P. Woessner, Jörn Görlach, Carol M. Hamilton, Neil E. Hoffman, Andreas S. Klöti, Adel Zayed, Robert A. Ascenzi
  • Patent number: 6383787
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: May 7, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6358719
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355458
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355459
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355457
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6346404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach